Ani Pharmaceuticals (ANIP) Current Assets (2010 - 2026)

Ani Pharmaceuticals has disclosed Current Assets across 17 years of filings, most recently posting $825.4 million for Q2 2026.

• In Q2 2026, Current Assets rose 36.97% year-over-year to $825.4 million; the TTM figure through Jun 2026 stood at $825.4 million (up 36.97% YoY), while the FY2025 annual figure was $753.1 million, up 42.51% from the prior year.
• Current Assets came in at $825.4 million for Q2 2026 at Ani Pharmaceuticals, up from $747.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $825.4 million in Q2 2026 to a low of $301.4 million in Q1 2022.
• Average Current Assets over 5 years is $523.7 million, with a median of $524.9 million recorded in 2024.
• Year-over-year, Current Assets soared 68.09% in 2022 and declined 0.79% in 2025.
• Over 5 years, Current Assets stood at $344.3 million in 2022, then surged by 50.99% to $519.8 million in 2023, then gained by 1.66% to $528.5 million in 2024, then surged by 42.51% to $753.1 million in 2025, then grew by 9.6% to $825.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $825.4 million in Q2 2026, $747.1 million in Q1 2026, and $753.1 million in Q4 2025.